JP2018501322A - トール様受容体４アンタゴニストの炎症促進性およびアジュバント機能 - Google Patents

トール様受容体４アンタゴニストの炎症促進性およびアジュバント機能 Download PDF

Info

Publication number
JP2018501322A
JP2018501322A JP2017555445A JP2017555445A JP2018501322A JP 2018501322 A JP2018501322 A JP 2018501322A JP 2017555445 A JP2017555445 A JP 2017555445A JP 2017555445 A JP2017555445 A JP 2017555445A JP 2018501322 A JP2018501322 A JP 2018501322A
Authority
JP
Japan
Prior art keywords
oxpapc
lps
caspase
inflammasome
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017555445A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018501322A5 (cg-RX-API-DMAC7.html
Inventor
ジョナサン シー． カガン，
ジョナサン シー． カガン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Childrens Hospital
Original Assignee
Boston Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Childrens Hospital filed Critical Boston Childrens Hospital
Publication of JP2018501322A publication Critical patent/JP2018501322A/ja
Publication of JP2018501322A5 publication Critical patent/JP2018501322A5/ja
Priority to JP2020213210A priority Critical patent/JP7410845B2/ja
Priority to JP2020213211A priority patent/JP7410846B2/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2017555445A 2015-01-12 2016-01-12 トール様受容体４アンタゴニストの炎症促進性およびアジュバント機能 Pending JP2018501322A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2020213210A JP7410845B2 (ja) 2015-01-12 2020-12-23 トール様受容体４アンタゴニストの炎症促進性およびアジュバント機能
JP2020213211A JP7410846B2 (ja) 2015-01-12 2020-12-23 トール様受容体４アンタゴニストの炎症促進性およびアジュバント機能

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562102245P 2015-01-12 2015-01-12
US62/102,245 2015-01-12
PCT/US2016/012994 WO2016115097A2 (en) 2015-01-12 2016-01-12 Pro-inflammatory and adjuvant functions of toll-like receptor 4 antagonists

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2020213210A Division JP7410845B2 (ja) 2015-01-12 2020-12-23 トール様受容体４アンタゴニストの炎症促進性およびアジュバント機能
JP2020213211A Division JP7410846B2 (ja) 2015-01-12 2020-12-23 トール様受容体４アンタゴニストの炎症促進性およびアジュバント機能

Publications (2)

Publication Number Publication Date
JP2018501322A true JP2018501322A (ja) 2018-01-18
JP2018501322A5 JP2018501322A5 (cg-RX-API-DMAC7.html) 2019-02-28

Family

ID=56406560

Family Applications (7)

Application Number Title Priority Date Filing Date
JP2017555445A Pending JP2018501322A (ja) 2015-01-12 2016-01-12 トール様受容体４アンタゴニストの炎症促進性およびアジュバント機能
JP2020213210A Active JP7410845B2 (ja) 2015-01-12 2020-12-23 トール様受容体４アンタゴニストの炎症促進性およびアジュバント機能
JP2020213211A Active JP7410846B2 (ja) 2015-01-12 2020-12-23 トール様受容体４アンタゴニストの炎症促進性およびアジュバント機能
JP2023015026A Active JP7719815B2 (ja) 2015-01-12 2023-02-03 トール様受容体４アンタゴニストの炎症促進性およびアジュバント機能
JP2023015047A Active JP7719816B2 (ja) 2015-01-12 2023-02-03 トール様受容体４アンタゴニストの炎症促進性およびアジュバント機能
JP2025041931A Pending JP2025094038A (ja) 2015-01-12 2025-03-14 トール様受容体４アンタゴニストの炎症促進性およびアジュバント機能
JP2025041934A Pending JP2025090801A (ja) 2015-01-12 2025-03-14 トール様受容体４アンタゴニストの炎症促進性およびアジュバント機能

Family Applications After (6)

Application Number Title Priority Date Filing Date
JP2020213210A Active JP7410845B2 (ja) 2015-01-12 2020-12-23 トール様受容体４アンタゴニストの炎症促進性およびアジュバント機能
JP2020213211A Active JP7410846B2 (ja) 2015-01-12 2020-12-23 トール様受容体４アンタゴニストの炎症促進性およびアジュバント機能
JP2023015026A Active JP7719815B2 (ja) 2015-01-12 2023-02-03 トール様受容体４アンタゴニストの炎症促進性およびアジュバント機能
JP2023015047A Active JP7719816B2 (ja) 2015-01-12 2023-02-03 トール様受容体４アンタゴニストの炎症促進性およびアジュバント機能
JP2025041931A Pending JP2025094038A (ja) 2015-01-12 2025-03-14 トール様受容体４アンタゴニストの炎症促進性およびアジュバント機能
JP2025041934A Pending JP2025090801A (ja) 2015-01-12 2025-03-14 トール様受容体４アンタゴニストの炎症促進性およびアジュバント機能

Country Status (6)

Country Link
US (7) US20180318414A1 (cg-RX-API-DMAC7.html)
EP (1) EP3244923B1 (cg-RX-API-DMAC7.html)
JP (7) JP2018501322A (cg-RX-API-DMAC7.html)
AU (2) AU2021200638B2 (cg-RX-API-DMAC7.html)
CA (1) CA2973585A1 (cg-RX-API-DMAC7.html)
WO (1) WO2016115097A2 (cg-RX-API-DMAC7.html)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022521831A (ja) * 2019-03-29 2022-04-12 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 標的指向性協働的がん免疫療法
JP2022552200A (ja) * 2019-10-07 2022-12-15 ノースウエスト バイオセラピューティクス，インコーポレイティド 樹状細胞およびＴ細胞の活性化を増強するためのならびにＴＨ－１免疫応答を誘導するためのｉｎ ｖｉｔｒｏの方法および組成物
JP2023502400A (ja) * 2019-11-18 2023-01-24 ザ・チルドレンズ・メデイカル・センター・コーポレーシヨン がん免疫療法のために常在型樹状細胞を超活性化する刺激
JP2023503427A (ja) * 2019-11-18 2023-01-30 ザ・チルドレンズ・メデイカル・センター・コーポレーシヨン 超活性樹状細胞は養子細胞移植に基づく持続性抗腫瘍免疫を可能にする

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180318414A1 (en) 2015-01-12 2018-11-08 Children's Medical Center Corporation Pro-Inflammatory and Adjuvant Functions of Toll-Like Receptor 4 Antagonists
EP3538138A1 (en) * 2016-11-14 2019-09-18 Dana Farber Cancer Institute, Inc. Compositions and methods of treating cancer
CN114894910B (zh) * 2022-03-18 2023-10-20 重庆医科大学附属第一医院 1-棕榈酰-2-花生四烯酰-sn-甘油-3-磷酸胆碱检测试剂的新用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04503363A (ja) * 1989-07-12 1992-06-18 ウイスコンシン　アラムナイ　リサーチ　フオンデーシヨン 新規リピドａ誘導体およびその用途

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
PT659439E (pt) 1993-12-24 2002-04-29 Merck Patent Gmbh Imunoconjugados
JP3595264B2 (ja) 1998-11-03 2004-12-02 デ・スタート・デル・ネーデルランデン・ベルテゲンボールディクト・ドール・デ・ミニステル・バン・ベルジーン・ボルクスゲツォントヘイト・エン・クルトゥール 遺伝的に修飾されたグラム陰性細菌由来の低毒性ｌｐｓ
WO2004006910A1 (de) 2002-07-15 2004-01-22 Norbert Leitinger Lipidoxidationsprodukte zur hemmung von entzündungen
US20060257359A1 (en) 2005-02-28 2006-11-16 Cedric Francois Modifying macrophage phenotype for treatment of disease
US8961982B2 (en) 2005-12-16 2015-02-24 The Regents Of The University Of California Modulation of developmental immune programming and protection against cardiovascular disease, diabetes, infectious diseases, and cancer
JP2010505883A (ja) * 2006-10-12 2010-02-25 ザ ユニバーシティー オブ クイーンズランド 免疫応答を調節するための組成物および方法
JP5620179B2 (ja) 2009-07-27 2014-11-05 株式会社神戸製鋼所 配線構造およびその製造方法、並びに配線構造を備えた表示装置
ES2769326T3 (es) 2010-02-05 2020-06-25 Univ Cornell Métodos y composiciones para la inmunoterapia contra el cáncer usando células tumorales que expresan la proteína de fusión de flagelina y antígeno asociado al tumor
CA2798074A1 (en) 2010-04-27 2011-11-03 The Johns Hopkins University Immunogenic compositions and methods for treating neoplasia
WO2012177624A2 (en) 2011-06-21 2012-12-27 The Johns Hopkins University Focused radiation for augmenting immune-based therapies against neoplasms
EP2791101B1 (en) 2011-12-12 2019-09-18 Vascular Biogenics Ltd. Treatment of non-alcoholic steatohepatitis
WO2014164699A1 (en) * 2013-03-11 2014-10-09 The Regents Of The University Of California Herpes virus vaccines and treatments
US10253294B2 (en) 2013-12-18 2019-04-09 Julius-Maximilians-Universität Würzburg Galactose oxidase treatment of dendritic cells to improve their immunogenicity
US20180318414A1 (en) 2015-01-12 2018-11-08 Children's Medical Center Corporation Pro-Inflammatory and Adjuvant Functions of Toll-Like Receptor 4 Antagonists
EP3291821A4 (en) 2015-05-07 2019-03-20 Baylor College of Medicine IMMUNOTHERAPY WITH DENDRITIC CELLS
CN108697778B (zh) 2016-02-16 2023-10-03 哈佛学院院长等 病原体疫苗及其生产和使用方法
WO2018004747A1 (en) 2016-06-27 2018-01-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Therapeutic antitumor combination of a tlr4 ligand with other treatments
WO2018067302A2 (en) 2016-09-19 2018-04-12 North Western University Therapeutic effects of cellular delivery of small molecules and macromolecules with liposomal spherical nucleic acids
KR20250159271A (ko) 2018-05-03 2025-11-10 엘.이.에이.에프. 홀딩스 그룹 엘엘씨. 카로티노이드 조성물 및 이의 용도
CN115461073A (zh) 2019-10-07 2022-12-09 西北生物治疗药物公司 用于增强树突细胞和T细胞激活以及用于诱导Th-1免疫应答的体外方法和组合物
CA3163173A1 (en) 2019-11-18 2021-05-27 Children's Medical Center Corporation Hyperactive dendritic cells enable durable adoptive cell transfer-based anti-tumor immunity
CN114980919A (zh) 2019-11-18 2022-08-30 儿童医学中心公司 过度活化驻留树突状细胞的刺激物用于癌症免疫疗法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04503363A (ja) * 1989-07-12 1992-06-18 ウイスコンシン　アラムナイ　リサーチ　フオンデーシヨン 新規リピドａ誘導体およびその用途

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FRUHWIRTH, G. O. ET AL., BIOCHIMICA ET BIOPHYSICA ACTA - MOLECULAR BASIS OF DISEASE, vol. 1772, no. 7, JPN6019040159, 2007, pages 718 - 736, ISSN: 0004331869 *
GUNDACKER, N.C. ET AL., JOURNAL OF PROTEOME RESEARCH, vol. 8, no. 6, JPN6019040156, 2009, pages 2799 - 2811, ISSN: 0004331868 *
青枝大貴ら, DRUG DELIVERY SYSTEM, vol. 27, no. 1, JPN6019040157, 2012, pages 19 - 27, ISSN: 0004331867 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022521831A (ja) * 2019-03-29 2022-04-12 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 標的指向性協働的がん免疫療法
JP2022552200A (ja) * 2019-10-07 2022-12-15 ノースウエスト バイオセラピューティクス，インコーポレイティド 樹状細胞およびＴ細胞の活性化を増強するためのならびにＴＨ－１免疫応答を誘導するためのｉｎ ｖｉｔｒｏの方法および組成物
JP2023502400A (ja) * 2019-11-18 2023-01-24 ザ・チルドレンズ・メデイカル・センター・コーポレーシヨン がん免疫療法のために常在型樹状細胞を超活性化する刺激
JP2023503427A (ja) * 2019-11-18 2023-01-30 ザ・チルドレンズ・メデイカル・センター・コーポレーシヨン 超活性樹状細胞は養子細胞移植に基づく持続性抗腫瘍免疫を可能にする
JP7753205B2 (ja) 2019-11-18 2025-10-14 ザ・チルドレンズ・メデイカル・センター・コーポレーシヨン 超活性樹状細胞は養子細胞移植に基づく持続性抗腫瘍免疫を可能にする

Also Published As

Publication number Publication date
US12053522B2 (en) 2024-08-06
WO2016115097A2 (en) 2016-07-21
JP2025094038A (ja) 2025-06-24
US20240415957A1 (en) 2024-12-19
JP2023055883A (ja) 2023-04-18
AU2021200638B2 (en) 2024-06-06
US20200405848A1 (en) 2020-12-31
EP3244923A2 (en) 2017-11-22
WO2016115097A3 (en) 2016-09-09
AU2024219454A1 (en) 2024-10-03
JP2025090801A (ja) 2025-06-17
US20180318414A1 (en) 2018-11-08
JP7410846B2 (ja) 2024-01-10
AU2016206965A1 (en) 2017-08-31
US12070499B2 (en) 2024-08-27
EP3244923C0 (en) 2025-10-01
EP3244923B1 (en) 2025-10-01
JP7410845B2 (ja) 2024-01-10
EP3244923A4 (en) 2018-09-05
AU2016206965B2 (en) 2021-03-04
US20250025552A1 (en) 2025-01-23
JP2023055880A (ja) 2023-04-18
US20200405847A1 (en) 2020-12-31
AU2021200638A1 (en) 2021-03-04
US11351250B2 (en) 2022-06-07
US20230042429A1 (en) 2023-02-09
US20230053338A1 (en) 2023-02-23
JP2021059570A (ja) 2021-04-15
JP7719816B2 (ja) 2025-08-06
JP2021059571A (ja) 2021-04-15
CA2973585A1 (en) 2016-07-21
US11400153B2 (en) 2022-08-02
JP7719815B2 (ja) 2025-08-06

Similar Documents

Publication Publication Date Title
JP7719815B2 (ja) トール様受容体４アンタゴニストの炎症促進性およびアジュバント機能
Barbet et al. TAP dysfunction in dendritic cells enables noncanonical cross-presentation for T cell priming
Gambuzza et al. Targeting Toll-like receptors: emerging therapeutics for multiple sclerosis management
KR20210074277A (ko) T 세포 수용체 구축물 및 이의 용도
JP2019214573A (ja) ｐ５３変異体を再活性化することの可能なペプチド
Zhu et al. Activation of the NLRP3 inflammasome by vault nanoparticles expressing a chlamydial epitope
Thakur et al. Intrapulmonary (i. pulmon.) pull immunization with the tuberculosis subunit vaccine candidate H56/CAF01 after intramuscular (im) priming elicits a distinct innate myeloid response and activation of antigen-presenting cells than im or i. pulmon. prime immunization alone
Aichinger et al. Adjuvating the adjuvant: facilitated delivery of an immunomodulatory oligonucleotide to TLR9 by a cationic antimicrobial peptide in dendritic cells
US20230035037A1 (en) Teipp peptide variant and uses thereof
KR20230029857A (ko) 시스-결합 시글렉 작용제 및 관련 조성물 및 방법
김철균 Enhancement of cross-presentation in dendritic cells by modulation of cytosolic antigen or fatty acid metabolism
Fleshner et al. In vivo tissue source and releasing signal for endogenous extracellular Hsp72
Chin Functional and mechanistic studies on engineered antibodies that engage TRIM21
Cummings The Role Of Phosphoinositide 3-Kinase Gamma In The Host Immune Response Against Cutaneous Leishmaniasis Caused by Leishmania mexicana
Rodino Orientia tsutsugamushi Modulates Endoplasmic Reticulum Stress to Benefit its Intracellular Growth and Targets NLRC5 to Inhibit Major Histocompatibility Complex I Expression
Jabir The interactions between inflammasome activation and induction of autophagy following Pseudomonas aeruginosa infection
Zaccard Tunneling nanotube networks in dendritic cell communication and HIV-1 trans-infection
Bennett Intracellular membrane traffic of class I major histocompatibility complex molecules and transferrin receptor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190115

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190115

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191018

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200420

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200825